Eli Lilly to Invest US$6.5 Billion in Houston, Texas, USA

Introduction:

Eli Lilly and Company has announced plans to invest US$6.5 billion to build a new active pharmaceutical ingredient (API) manufacturing facility at Generation Park in Houston, Texas, USA.

Features:

The project involves the construction of an active pharmaceutical ingredient (API) manufacturing facility at Generation Park in Houston, Texas, USA. The facility will focus on producing APIs for small-molecule medicines used in cardiometabolic health, oncology, immunology and neuroscience.

The facility will also manufacture orforglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity treatment. Production will support the medicine’s manufacturing requirements, subject to regulatory approval.

The manufacturing site will incorporate chemical synthesis processes for producing APIs used in pharmaceutical formulations. These ingredients will be used in the development and manufacture of medicines across the planned therapeutic areas.

The facility will use machine learning, artificial intelligence (AI), digitally integrated systems and advanced data analytics in its manufacturing operations. Digital automation will be incorporated across the site to support process monitoring and manufacturing activities.

Construction is expected to be completed and the facility to become operational by 2031.

Specifications:

Name

Eli Lilly and Company

Type

New Construction

Budget

US$6.5 billion

Year

2031